ExpreS2ion Biotech Holding AB (FRA:5JD0) EBIT: €-3.96 Mil (TTM As of Mar. 2026)


FRA:5JD0 ExpreS2ion Biotech Holding AB FRA:5JD0
41 GF Score
Price €0.04
GF Value €0.08
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB EBIT?

ExpreS2ion Biotech Holding AB FRA:5JD0 -3.63% 41 EBIT is €-3.96 Mil as of Mar. 2026. GuruFocus rates FRA:5JD0 with a GF Score™ of 41/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review.

ExpreS2ion Biotech Holding AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-1.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.96 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ExpreS2ion Biotech Holding AB's annualized ROC % for the quarter that ended in Mar. 2026 was -126.31%. ExpreS2ion Biotech Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -13,000.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ExpreS2ion Biotech Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 140.92%.

ExpreS2ion Biotech Holding AB  (FRA:5JD0) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ExpreS2ion Biotech Holding AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-4.436 * ( 1 - 20.46% )/( (2.922 + 2.665)/ 2 )
=-3.5283944/2.7935
=-126.31 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.983 - 0.372 - ( 4.37 - max(0, 2.597 - 5.286+4.37))
=2.922

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.679 - 0.152 - ( 2.028 - max(0, 2.132 - 3.994+2.028))
=2.665

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

ExpreS2ion Biotech Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.42/( ( (0.043 + max(-1.73, 0)) + (0.025 + max(-1.177, 0)) )/ 2 )
=-4.42/( ( 0.043 + 0.025 )/ 2 )
=-4.42/0.034
=-13,000.00 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.109 + 0 + 0.712) - (0.372 + 0 + 2.179)
=-1.73

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.095 + 0 + 0.812) - (0.152 + 0 + 1.932)
=-1.177

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ExpreS2ion Biotech Holding AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-3.964/-2.813
=140.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB EBIT Related Terms

ExpreS2ion Biotech Holding AB EBIT Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB EBIT Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.63 -11.44 -8.89 -3.81 -4.02

ExpreS2ion Biotech Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.13 -1.06 -0.88 -0.91 -1.11

FRA:5JD0 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ExpreS2ion Biotech Holding AB EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's EV-to-EBIT falls into.


FRA:5JD0
41GF Score
ExpreS2ion Biotech Holding AB FRA:5JD0
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-3.96 Mil mean?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a EBIT of €-3.96 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ExpreS2ion Biotech Holding AB.
Is ExpreS2ion Biotech Holding AB's EBIT too high?
ExpreS2ion Biotech Holding AB's current EBIT is €-3.96 Mil. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's EBIT compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's EBIT of €-3.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ExpreS2ion Biotech Holding AB. ExpreS2ion Biotech Holding AB's current EBIT is €-3.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a current EBIT of €-3.96 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.04 — trading 53.5% below its estimated fair value. The current EBIT is €-3.96 Mil. ExpreS2ion Biotech Holding AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current EBIT is €-3.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of €0.04 is trading 53.5% below its estimated GF Value™ of €0.08.

Key valuation signals for FRA:5JD0:

  • EBIT: €-3.96 Mil
  • GF Value™: €0.08 vs. price of €0.04 (53.5% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ExpreS2ion Biotech Holding AB Business Description

Other Exchanges EXPRS2:Sweden
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
41GF Score

Get the complete analysis for FRA:5JD0

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.04
Price
€0.08
GF Value